Behavioral and cognitive performance of humanized APOEε3/ε3 liver mice in relation to plasma apolipoprotein E levels.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
31 01 2023
Historique:
received: 07 08 2022
accepted: 13 01 2023
entrez: 31 1 2023
pubmed: 1 2 2023
medline: 3 2 2023
Statut: epublish

Résumé

Plasma apolipoprotein E levels were previously associated with the risk of developing Alzheimer's disease (AD), levels of cerebrospinal fluid AD biomarkers, cognition and imaging brain measures. Outside the brain, the liver is the primary source of apoE and liver transplantation studies have demonstrated that liver-derived apoE does not cross the blood-brain-barrier. How hepatic apoE may be implicated in behavioral and cognitive performance is not clear. In the current study, we behaviorally tested FRGN mice with humanized liver harboring the ε3/ε3 genotype (E3-human liver (HL)) and compared their behavioral and cognitive performance with that of age-matched ε3/ε3 targeted replacement (E3-TR) mice, the latter produces human apoE3 throughout the body whereas the E3-HL mice endogenously produce human apoE3 only in the liver. We also compared the liver weights and plasma apoE levels, and assessed whether plasma apoE levels were correlated with behavioral or cognitive measures in both models. E3-HL were more active but performed cognitively worse than E3-TR mice. E3-HL mice moved more in the open field containing objects, showed higher activity levels in the Y maze, showed higher activity levels during the baseline period in the fear conditioning test than E3-TR mice, and swam faster than E3-TR mice during training to locate the visible platform in the water maze. However, E3-HL mice showed reduced spatial memory retention in the water maze and reduced fear learning and contextual and cued fear memory than E3-TR mice. Liver weights were greater in E3-HL than E3-TR mice and sex-dependent only in the latter model. Plasma apoE3 levels were similar to those found in humans and comparable in female and male E3-TR mice but higher in female E3-HL mice. Finally, we found correlations between plasma apoE levels and behavioral and cognitive measures which were predominantly model-dependent. Our study demonstrates mouse-model dependent associations between plasma apoE levels, behavior and cognition in an 'AD-neutral' setting and suggests that a humanized liver might be sufficient to induce mouse behavioral and cognitive phenotypes.

Identifiants

pubmed: 36720957
doi: 10.1038/s41598-023-28165-3
pii: 10.1038/s41598-023-28165-3
pmc: PMC9889814
doi:

Substances chimiques

Apolipoprotein E3 0
Apolipoproteins E 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1728

Subventions

Organisme : NIH HHS
ID : RF1 AG059088
Pays : United States

Informations de copyright

© 2023. The Author(s).

Références

Nat Metab. 2021 Feb;3(2):274-286
pubmed: 33619379
J Biol Chem. 2016 Dec 30;291(53):27204-27218
pubmed: 27793990
Nat Rev Neurol. 2019 Sep;15(9):501-518
pubmed: 31367008
Front Behav Neurosci. 2021 Jun 11;15:680042
pubmed: 34177480
Mol Neurodegener. 2019 Oct 17;14(1):37
pubmed: 31623648
J Biol Chem. 2014 Apr 18;289(16):11282-11292
pubmed: 24599963
Front Behav Neurosci. 2010 Sep 30;4:
pubmed: 20953248
Exp Neurol. 1995 Dec;136(2):107-22
pubmed: 7498401
Int J Alzheimers Dis. 2011 Apr 05;2011:974361
pubmed: 21559182
JAMA Netw Open. 2020 Jul 1;3(7):e209250
pubmed: 32648923
PLoS One. 2013 Nov 04;8(11):e78550
pubmed: 24223822
Front Behav Neurosci. 2022 Feb 08;16:791128
pubmed: 35210996
Behav Genet. 2000 Jul;30(4):285-93
pubmed: 11206083
Curr Opin Neurobiol. 2009 Jun;19(3):305-10
pubmed: 19375301
Gastroenterology. 2015 Sep;149(3):728-40.e15
pubmed: 26028580
Neurobiol Aging. 2011 Jan;32(1):75-84
pubmed: 19178986
PLoS One. 2016 Feb 01;11(2):e0148099
pubmed: 26828652
Front Behav Neurosci. 2018 Jul 18;12:140
pubmed: 30072879
J Alzheimers Dis. 2019;71(4):1217-1231
pubmed: 31524156
J Biol Chem. 1997 Jul 18;272(29):17972-80
pubmed: 9218423
PLoS Biol. 2021 Sep 14;19(9):e3001358
pubmed: 34520451
Behav Neurosci. 1992 Apr;106(2):274-85
pubmed: 1590953
Behav Brain Res. 2001 Nov 1;125(1-2):269-77
pubmed: 11682118
Nat Rev Neurosci. 2013 Jun;14(6):417-28
pubmed: 23635870
J Clin Invest. 1991 Jul;88(1):270-81
pubmed: 2056122
Dement Geriatr Cogn Disord. 2015;39(3-4):154-66
pubmed: 25547651
J Neurosci Methods. 1984 May;11(1):47-60
pubmed: 6471907
Science. 1988 Apr 29;240(4852):622-30
pubmed: 3283935
Nat Biotechnol. 2007 Aug;25(8):903-10
pubmed: 17664939
Methods Mol Biol. 2019;1916:105-111
pubmed: 30535688
J Alzheimers Dis. 2021;81(1):339-354
pubmed: 33814450
Sci Rep. 2021 Feb 25;11(1):4678
pubmed: 33633159
Mol Psychiatry. 2022 Aug;27(8):3533-3543
pubmed: 35418601
Acta Neuropathol. 2014 May;127(5):633-43
pubmed: 24633805
Front Physiol. 2021 Sep 27;12:746509
pubmed: 34646164
Behav Brain Res. 2015 May 15;285:53-9
pubmed: 25655511
Cell. 2016 Dec 1;167(6):1469-1480.e12
pubmed: 27912057
Hepatology. 2020 Aug;72(2):656-670
pubmed: 31785104
Alzheimers Res Ther. 2017 Jan 30;9(1):5
pubmed: 28137305
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10914-9
pubmed: 9724804
Transl Psychiatry. 2022 Mar 28;12(1):125
pubmed: 35347119
Neuropsychopharmacology. 2015 Sep;40(10):2443-53
pubmed: 25857685
Neurobiol Aging. 2012 Feb;33(2):345-58
pubmed: 20400205
Alzheimers Dement. 2020 Dec;16(12):1624-1637
pubmed: 32808727
Nat Genet. 1994 Jun;7(2):180-4
pubmed: 7920638
Neuromolecular Med. 2021 Mar;23(1):99-117
pubmed: 33085065
PLoS One. 2018 Sep 7;13(9):e0203659
pubmed: 30192871
J Neurosci. 2000 Mar 1;20(5):2064-71
pubmed: 10684907
Neuron. 2022 Apr 20;110(8):1304-1317
pubmed: 35298921
Methods Mol Biol. 2010;640:491-509
pubmed: 20645070
JAMA Netw Open. 2019 Jul 3;2(7):e197978
pubmed: 31365104
Lipids Health Dis. 2022 Jan 14;21(1):9
pubmed: 35027074

Auteurs

Kat Kessler (K)

Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, 97239, USA.

Andreas Giannisis (A)

Department of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden.

Greg Bial (G)

Yecuris Corporation, Tualatin, OR, 97062, USA.

Lander Foquet (L)

Yecuris Corporation, Tualatin, OR, 97062, USA.

Henrietta M Nielsen (HM)

Department of Biochemistry and Biophysics, Stockholm University, 10691, Stockholm, Sweden. henrietta.nielsen@dbb.su.se.

Jacob Raber (J)

Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, OR, 97239, USA. raberj@ohsu.edu.
Departments of Neurology and Radiation Medicine, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Portland, OR, 97239, USA. raberj@ohsu.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH